methylenebis(acrylamide) | 2240-98-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methylenebis(acrylamide)
• 英文别名: Methylene-bisacrylamide；hepta-2,5-dienediamide
• CAS: 2240-98-4
• 化学式: C₇H₁₀N₂O₂
• 分子量: 154.169
• InChiKey: FIKFOOMAUXPBJM-UHFFFAOYSA-N

物化性质

• 沸点：
  506.9±50.0 °C(Predicted)
• 密度：
  1.159±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  86.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Dimethylhexanediamine 、 methylenebis(acrylamide) 、 poly(propylenglycol)bis(2-aminopropylether) 在 水 、 甲醇 作用下， 以 水 为溶剂， 反应 144.0h， 以An elastic opaque white gel was obtained (89% yield)的产率得到dimethylhexanediamine methylene-bis-acrylamide Jeffamine
  参考文献：
  名称：

  Polyetheramidoamine hydrogels as heparinizable materials

  摘要：

  本文描述了能够在生理条件下与肝素形成复合物的聚醚酰胺胺水凝胶材料。这些材料在制造医疗器械方面非常有用。

  公开号：

  US05606012A1
• 作为试剂：
  描述：

  丙烯酰胺 、 丙烯酸 、 氢氧化钾 、 disodium;sulfonatooxy sulfate 、 双氧水 、 维生素 C 、 2-[(1-amino-1-imino-2-methylpropan-2-yl)diazenyl]-2-methylpropanimidamide;hydron;dichloride 以 methylenebis(acrylamide) 、 水 为溶剂， 反应 0.17h， 生成 Potassium;prop-2-enimidate;prop-2-enoic acid
  参考文献：
  名称：

  Cross-linked synthetic polymers having a porous structure, a high

  摘要：

  本发明涉及基于丙烯酸及其衍生物的交联合成聚合物，其具有高吸水能力和改善的吸水速度，可用于水、水溶液和体液的吸收，以及一种在自由基聚合条件下制备这些聚合物的方法，该方法获得具有多孔结构和吸水度相关的颗粒密度的聚合物，使得聚合物颗粒在水或水溶液中可以浮动。本发明还涉及这些聚合物用于吸收和/或保持水，并将水和/或活性物质溶液释放到周围介质中。聚合物的多孔结构由分散在聚合物中的氮形成，至少添加一种偶氮化合物作为聚合引发剂和发泡剂的水性单体溶液，该偶氮化合物在30℃至120℃温度下具有至少10小时的半衰期。

  公开号：

  US05856370A1

文献信息

• FUNCTIONALIZED COPOLYMERS AND USE THEREOF
  申请人：3M INNOVATIVE PROPERTIES COMPANY

  公开号：US20210031152A1

  公开（公告）日：2021-02-04

  An article that includes a functionalized copolymer and the use thereof, particularly in a process for binding biomaterials, such as in a process for separating aggregated proteins from monomeric proteins in a biological solution; wherein the article includes: a) a porous substrate; and b) a copolymer covalently attached to the porous substrate, the copolymer comprising a hydrocarbon backbone and a plurality of pendant groups attached to the hydrocarbon backbone, wherein 1) each of a first plurality of pendant groups comprises: (a) at least one acidic group or salt thereof; and (b) a spacer group that directly links the at least one acidic group or salt thereof to the hydrocarbon backbone by a chain of at least 6 catenated atoms; and 2) each of a second plurality of pendant groups comprises: (a) at least one acidic group or salt thereof; and (b) a spacer group that directly links the at least one acidic group or salt thereof to the hydrocarbon backbone by a chain of at least 6 catenated atoms; and wherein the first plurality of pendant groups are different than the second plurality of pendant groups; and wherein a mole ratio of the first plurality of pendant groups to the second plurality of pendant groups is in a range of 95:5 to 5:95.

  一篇包括功能化共聚物及其用途的文章，特别是在结合生物材料的过程中使用，例如在从生物溶液中分离聚集蛋白质和单体蛋白质的过程中；其中该文章包括：a) 多孔基底；和 b) 共价连接到多孔基底上的共聚物，该共聚物包括一个碳氢骨架和多个连接到碳氢骨架上的挂链基团，其中1) 第一多数挂链基团中的每一个包括：(a) 至少一个酸性基团或其盐；和 (b) 一个通过至少6个串联原子链直接将至少一个酸性基团或其盐连接到碳氢骨架的空间基团；和 2) 第二多数挂链基团中的每一个包括：(a) 至少一个酸性基团或其盐；和 (b) 一个通过至少6个串联原子链直接将至少一个酸性基团或其盐连接到碳氢骨架的空间基团；其中第一多数挂链基团不同于第二多数挂链基团；并且第一多数挂链基团与第二多数挂链基团的摩尔比在95:5到5:95的范围内。
• [EN] INHIBITORS OF NHE-MEDIATED ANTIPORT<br/>[FR] INHIBITEURS D'ANTIPORT À MÉDIATION PAR NHE
  申请人：ARDELYX INC

  公开号：WO2018129557A1

  公开（公告）日：2018-07-12

  The present disclosure is directed to compounds (Ι') and to their use in methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds (Ι') and their use in methods for the treatment of hypertension. The present disclosure is also directed to compounds (Ι') and to their use in methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

  本公开涉及化合物(Ι')及其在治疗与液体潴留或盐超负荷相关的疾病的方法中的用途，例如心力衰竭（尤其是充血性心力衰竭）、慢性肾病、终末期肾病、肝病以及过氧化物酶体增殖物激活受体（PPAR）gamma激动剂引起的液体潴留。本公开还涉及化合物(Ι')及其在治疗高血压的方法中的用途。本公开还涉及化合物(Ι')及其在治疗胃肠道疾病的方法中的用途，包括治疗或减少与胃肠道疾病相关的疼痛。
• [EN] COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS<br/>[FR] COMPOSÉS ET PROCÉDÉS DESTINÉS À INHIBER UN ANTIPORT MÉDIÉ PAR NHE DANS LE TRAITEMENT DES TROUBLES ASSOCIÉS À UNE RÉTENTION DE FLUIDE OU À UNE SURCHARGE DE SEL ET DES TROUBLES DU TRACTUS GASTRO-INTESTINAL
  申请人：ARDELYX INC

  公开号：WO2014029984A1

  公开（公告）日：2014-02-27

  The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist- induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

  本公开涉及化合物和治疗与液体潴留或盐过多有关的疾病的方法，例如心力衰竭（特别是充血性心力衰竭）、慢性肾病、晚期肾病、肝病和过氧化物酶体增殖物激活受体（PPAR）γ激动剂诱导的液体潴留。本公开还涉及化合物和治疗高血压的方法。本公开还涉及化合物和治疗胃肠道疾病的方法，包括治疗或减轻与胃肠道疾病相关的疼痛。
• [EN] PROCESSES FOR SEPARATING AGGREGATED PROTEINS FROM MONOMERIC PROTEINS IN A BIOLOGICAL SOLUTION<br/>[FR] PROCÉDÉS DE SÉPARATION DE PROTÉINES AGRÉGÉES À PARTIR DE PROTÉINES MONOMÈRES DANS UNE SOLUTION BIOLOGIQUE
  申请人：3M INNOVATIVE PROPERTIES CO

  公开号：WO2018048698A1

  公开（公告）日：2018-03-15

  A process for separating aggregated proteins from monomeric proteins in a biological solution, the process including: providing at least one filter element having a contacting surface, wherein the filter element comprises filter media comprising: a porous substrate; and disposed on the porous substrate, a polymer comprising a hydrocarbon backbone and a plurality of pendant groups attached to the hydrocarbon backbone, wherein each of a first plurality of pendant groups comprises: (1) at least one acidic group or salt thereof; and (2) a spacer group that directly links the at least one acidic group or salt thereof to the hydrocarbon backbone by a chain of at least 6 catenated atoms; and allowing an initial biological solution to contact the contacting surface of the filter element under conditions effective to separate the aggregated proteins from the monomeric proteins such that a final biological solution includes purified monomeric proteins.

  一种从生物溶液中分离聚集蛋白质和单体蛋白质的方法，该方法包括：提供至少一个具有接触表面的过滤元件，其中过滤元件包括包括过滤介质的多孔基质；并且在多孔基质上设置了一种聚合物，该聚合物包括一个烃骨架和附着在烃骨架上的多个偏基团，其中第一多个偏基团中的每一个包括：（1）至少一个酸性基团或其盐；和（2）一个间隔基团，通过至少6个串联原子的链将至少一个酸性基团或其盐直接连接到烃骨架；并且允许初始生物溶液在有效条件下接触过滤元件的接触表面，以使聚集蛋白质与单体蛋白质分离，从而得到含有纯化单体蛋白质的最终生物溶液。
• [EN] COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS<br/>[FR] COMPOSÉS UTILES POUR LE TRAITEMENT DE TROUBLES DU TRACTUS DIGESTIF
  申请人：ARDELYX INC

  公开号：WO2018129552A1

  公开（公告）日：2018-07-12

  The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist- induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

  本公开涉及化合物和治疗与液体潴留或盐过多有关的疾病的方法，例如心力衰竭（特别是充血性心力衰竭）、慢性肾病、晚期肾病、肝病和过氧化物酶体增殖物激活受体（PPAR）γ激动剂诱导的液体潴留。本公开还涉及化合物和治疗高血压的方法。本公开还涉及化合物和治疗胃肠道疾病的方法，包括治疗或减轻与胃肠道疾病相关的疼痛。